Company intelligence / Profile preview

Norlase

Ballerup, Denmark

Ownership: Private
Employees: ~61
Development stage: Other

Overview

Norlase markets ultra-portable ophthalmic laser devices (LEAF, LION, ECHO, LYNX) for retina and glaucoma procedures. Devices are FDA 510(k) cleared and CE marked with rapid clinical adoption, used in major US and EU eye centers. Praised for compactness, wireless operation, and pattern scanning innovation, with evidence of strong sales and multiple industry awards in 2023 and 2025[2][6][8].

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Norlase.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norlase.

Explore the full profile